Healthcare

Zai Lab sells innovative medicines in China and Asia while advancing its own pipeline. Revenue has expanded sharply over time, losses have narrowed, and cash burn has improved, making the next phase of margin conversion and product uptake especially important to watch.

Xenon Pharmaceuticals is a neurology-focused biotech building around azetukalner, a late-stage epilepsy program with broader central nervous system potential. The company pairs a focused pipeline and low debt with meaningful clinical milestones that could reshape its scale.

Warby Parker blends eyewear retail with vision care through a growing mix of stores, online sales, eye exams, and contact lenses. Revenue growth and cash flow have improved notably, making its path from brand-led growth toward a more durable business worth a closer look.

GeneDx focuses on genetic testing for rare and inherited diseases, with rising scale in exome and genome sequencing. Revenue growth and gross profit have improved sharply, making the company a far stronger clinical genomics business than it was a few years ago.

Virbac is a specialized animal health company with global reach, strong margins, and disciplined balance-sheet management. Its mix of pet care, veterinary relationships, and steady cash generation makes it a name worth examining closely for long-term business quality.

Veracyte develops genomic tests that help guide cancer diagnosis and treatment decisions. The company has shifted into a stronger phase with rising revenue, positive earnings, robust cash flow, and minimal debt, making its progress worth a closer look.

TransMedics develops organ-preservation technology and transplant logistics services designed to increase organ utilization. Rapid revenue growth, rising profitability, and a stronger cash profile make it a closely watched name in a specialized but important healthcare market.